Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic ...

Shares of Agenus climbed after the clinical-stage immuno-oncology company triggered the first $20 million contingent payment under its strategic collaboration with Zydus Lifesciences. The stock jumped ...

Zydus Lifesciences will roll out generic semaglutide injections in India post-patent expiry, using a reusable single-pen ...

One of the standout features of Zydus' semaglutide offering is its unique, indigenously developed drug delivery system ...

India’s Zydus Lifesciences is in the FDA’s crosshairs once again, this time for a trio of unnamed violations at an injectables facility. Following an FDA inspection that wrapped up this week, Zydus, ...

(Fixes formatting in the last bullet) Feb 25 - Zydus Lifesciences will launch generic versions of semaglutide injections for obesity and diabetes in India after patent expiry of the Ozempic active ...

Zydus Targets First-Wave Entry in North American Immuno-Oncology Market with Keytruda® Biosimilar 🎯💊 | MCap 93,101.8 Cr - ...

Zydus has received the Food and Drug Administration’s permission for two generics. The FDA approved the company's dexamethasone tablets 1 mg. Dexamethasone is used to treat conditions such as ...

Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are already eying the blockbuster as a potential target. After two generics makers ...

Zydus to launch Semaglutide Injection in India, featuring a unique reusable pen for improved diabetes and obesity management.

Feb 12 (Reuters) - India's Zydus Lifesciences and its U.S. unit will pay $120 million ‌to Astellas Pharma as part of ‌a deal to settle a patent dispute over the Japanese drugmaker's bladder disorder ...

Zydus Cadila has completed (PDF) a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. The Indian company said the DNA vaccine ...